Thursday, November 19, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > Pfizer Partners with Tiny Biotech to Research Next-Gen Covid Treatment

Pfizer Partners with Tiny Biotech to Research Next-Gen Covid Treatment

in News, Uncategorized
Pfizer Partners with Tiny Biotech to Research Next-Gen Covid Treatment
Share on LinkedinShare on WhatsApp

On December 6th, Pfizer (NYSE: PFE) announced a research collaboration and exclusive license agreement with Clear Creek Bio — a 10-person biotech that has an office in Cambridge, MA, but operates fully remotely. This program will expand Pfizer’s innovative anti-infective pipeline and, if successful, will complement Pfizer’s existing portfolio of COVID-19 products with direct-acting antiviral agents against different SARS-CoV-2 targets.

“COVID-19 has proven to be a devastating and highly unpredictable disease, one with the potential to remain a global health concern for years to come,” said Charlotte Allerton, Chief Scientific Officer, Anti-Infectives and Head of Medicine Design, of Pfizer. “It is critical that we try to stay ahead of the virus, continuing to advance clinical development opportunities for our current oral therapy as well as innovating through our internal programs and strategic partnerships to bring forward additional monotherapy and/or combination treatment candidates that we believe may play a role in the ongoing fight against COVID-19.”

Under the terms of the agreement, the two companies will work together to identify an essential enzyme (PLpro), which plays an important role in viral replication. At which time Pfizer will be solely responsible for further development and commercialization activities. Clear Creek Bio will receive an undisclosed upfront payment and will be eligible to receive additional potential milestone payments plus royalties on future product sales.

Tags: Biotech industryCOVID-19Pfizer

Related Posts

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia shares rally following earnings beat

Target aims for non-alcoholic cocktail market ahead of the holiday season
News

Target reports its strongest sales growth in five years

Huang joins top CEOs on Trump’s China trip
News

Trump arrives in China for historic Xi, Putin meeting

The IMF-World Bank meetings commence in Washington
News

IMF chief gives stark warning on global economy 

Disney’s full year earnings prove streaming is successful
News

Disney beats earnings expectations as park attendance grows

Home Depot CFO delivers strategic update as company offers cautious forecast
News

Home Depot names Richard McPhail CEO amid leadership reshuffle

Nvidia due in Supreme Court today
News

Nvidia stock falls as execs push for Huang’s return

Warren Buffett Becomes HP Top Shareholder
News

Buffett donates $5.5 billion, urges kindness in Thanksgiving letter

Eli Lilly pledges $6 billion manufacturing plant in Alabama
News

Lilly to acquire Calytrix Bio in $1.5 billion deal

Trump pardons Founder and former CEO of Binance
News

$1.2 billion in stolen Binance crypto seized by U.S.

No Result
View All Result

Recent Posts

  • AI Has Entered the Boardroom. Who’s Overseeing It?
  • ‘Grand Theft Auto VI’ could be the biggest entertainment launch in history
  • Nvidia shares rally following earnings beat
  • Target reports its strongest sales growth in five years
  • Trump arrives in China for historic Xi, Putin meeting

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.